Real‐life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy‐cell leukemia: A multicenter Italian retrospective study (HCL‐PG03R)Enrico Tiacci, Andrea Bernardelli, Andrea Visentin et al.|HemaSphere|2025Cited by 1